The replacement of amino acids 1 and 3 of glycopeptide antibiotics (dalbaheptides) with new amino acids or other chemical entities suitable to interact with both glycopeptide-resistant (dAla-D-Lactate) and susceptible (D-Ala-D-Ala) targets is one of the chemical strategies currently followed to pursue activity against highly glycopeptide-resistant VanA enterococci while maintaining activity against glycopeptide-susceptible Gram-positive bacteria, particularly methicillin-resistant staphylococci. As a preliminary approach, the substitution of amino acid 1 of deglucoteicoplanin (TD) with D-lysine or D-methylleucine and of its amino acid 3 with L-phenylalanine or L-lysine was investigated.
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In this paper, the synthesis and in vitro antibacterial activities of first non-natural dalbaheptide methyl ester aglycons MDL63,166 (D-Lys1-Phe3-TD-DHP-Me), MDL64,945 (D-Lys1-Lys3-TD-DHP-Me), and MDL64,468 (D-MeLeu^Lys^TD-DHP-Me) are described. These compounds, which were obtained from intermediate TD-derived tetrapeptide methyl ester (TDTP-Me) according to a 9-step overall procedure, had excellent anti-staphylococcal activity. The most active derivative against staphylococci, MDL64,945 (MIC: 0.063 jUg/ml for S. aureus, S. epidermidis and S. haemolyticus) was inactive against VanAenterococci, while MDL63,166 and MDL64,468 were somewhat active against VanAstrains of E. faecalis; MDL64,468 was also moderately active against one VanA isolate of E. faecium and had marginal activity as TD against E. coli.
The increased interest for glycopeptides of the dalbaheptide family1} is related to the increasing incidence of serious and often multi-resistant Grampositive pathogens infecting hospital patients, such as the difficult-to-treat methicillin-resistant (Meth-R) Staphylococcus aureus (MRSA),as virulent pathogen of major importance, and coagulase-negative staphylococci (CNSt)1, as the most frequent cause of bacteremia particularly in immunocompromised patients. Currently commercially available glycopeptides vancomycin (V) 2) and teicoplanin (T)3) are extensively used in the treatment of severe infections caused by MRSAand CNSt as well as in the therapy of enterococcal infections. Infections due to enterococci have become a dramatic clinical problem since few antibacterial agents are efficacious against these refractory organisms and increasing resistance is rapidly eliminating the current JAN. 1997 options. The recent emergence and spread of resistance also to glycopeptides in VanAenterococci poses a serious threat for the future.4) Even some strains of Meth-R CNSt have reduced susceptibility to T and occasionally to V.5) It follows an urgent need for newmorepotent glycopeptides against multi-resistant Gram-positive pathogens which combine improved activity against Meth-R staphylococci with excellent activity against highly glycopeptide-resistant VanAenterococci.
Resistance to glycopeptides in VanAenterococci is due to a change in the structure of target peptide D-Ala-D-Ala which is replaced by a D-Ala-D-Lactate depsipeptide6)
that is not sufficiently bound by glycopeptides to prevent the bacterial growth. In the past decade, structure-activity relationships (SAR) established with chemical derivatives respectively. Deprotection of 2a with TFAgave 3a, while deprotection of the 7Va-amino group of the lysyl moiety of compound 2b with piperidine yielded 3b. The most challenging step was macrocyclization of 3a and 3b to hexapeptides 4a and 4b, respectively, which was carried out in the presence of hydroxybenzotriazole (HOBT), Af-methylmorpholine and DCC. Hydrogenolysis (H2, 5% Pd/C) of the TV-terminal CBZ group of 4a and 4b gave hexapeptides 5a and 5b, respectively. Reaction of 5a or 5b with di-Boc-D-Lys, NSu ester, produced Scheme 6. Introduction of AA3(L-His) and cyclization. protons of the Lys moiety whose chemical shift value is Structure Elucidation at very high field. This can be interpreted as due to the The structures of intermediates 7V-CBZ-protected shielding effect exerted on this CH2by the amide carbonyl hexapeptide 4a, CBZ, BOC-diprotected hexapeptide 4b, group of Lys itself in the peptide chain. di-BOC-protected heptapeptide 6c (Tables 2 and 3) , and In Table 5 , the XHNMRassignments for some selected those of MDL63,166, MDL64,945 and MDL64,468 protons in the left-hand part of the molecules of these (Table 4) were determined by XHNMRand confirmed new dalbaheptides are given in comparison with those by electrospray ionization mass spectrometry (ESI-MS). of corresponding TD-protons. The similarities with the The XHNMRspectra attributions (Tables 4 and 5) latter compound suggest that the stereochemistry and were based on COSYproton-proton correlations and on the 3D structure in the left-hand part of these molecules comparison with data reported for TD.15) Assignments are unchanged. The strong change in the chemical shift concern amino acid residues 1 and 3 which replace those of proton 4b suggests that along with chemical modificaof TDmethyl ester (TD-Me) in these positions. The tion this part of the molecule also experiences a 3D
reported chemical shift values are not significantly change. aThe proton nomenclature is that adopted for TD.15) By analogy with the proton nomenclature adopted for glycopeptides, HCaprotons of amino acid fragments (n= 1 to 7) are indicated with symbol "xn", CH(OH) or CH2 benzyl protons are defined as zn or zn, z'n, while symbol wnis used for NHor NH2protons. Aromatic, benzylic and HCaprotons are defined as described in ref. 15. glycopeptides, including the methyl ester (TD-Me) of TDm,were devoid of activity against these bacteria. The inactivity of MDL64,945 against Gram-negative E. coll was unexpected since the two lysines in positions 1 and 3 were thought to promote penetration through the Gram-negative outer membrane according to a mechanism of self-promoted uptake. 16) However, a commonproperty of these three comt ft In a separate experiment, also the methyl ester of the aglycon of V-type glycopeptide eremomycin^(a sample of this compoundwas supplied from the Inst. NewAntibiotics, Moscow)was inactive against these strains ofVanAenterococci; unpublished results, Lepetit Research Center laboratories. Gram-positive pathogens could be pursued by replacement of amino acids 1 and 3 in the heptapeptide structure and also confirm the importance of the structure of these amino acids for the activity of dalbaheptides.
Experimental

HPLC Methods
Reactions, column eluates and final products were checked by HPLC. recorded at 280nm by UV variable detector. These compounds were purified using a HPLCsemipreparative column Zorbax ODS(250 mmx 9.4 mmi.d.; particle size 10 jjm, injection volume 500 jjI). The elution systems used were as follows:
1-H NMR
The XH NMRspectra were recorded in DMSO-d6 solution at 303°K on a Bruker AM500 NMR-spectrometer equipped with an Aspect 3000 computer, using Me4Si (delta, 0.00 ppm) as internal reference. Signal assignments in the *H NMR spectra of compounds 4b and 6c were accomplished using DQCOSY and ROESY experiments. In these cases, NMR spectra were recorded on a Varian VXR-400 spectrometer at 323°K. From the DQCOSY spectra were identified three ABX-spin systems which belong to the aromatic rings 2, 5, 6 and two AX-spin systems which belong to the protons of the aromatic rings 4 and 7. The signals of x2, x3, x4, x5, x6, x7 protons were detected from ROESYexperiments. The combination of DQCOSY and ROESYdata allowed the assignment of all remaining protons.
ESI-MS
An APIIII+triple quadrupole mass spectrometer (PE-Sciex, Thornhill, ON, Canada) equipped with an articulated ion spray interface was employed. Tuning and calibration were performed on both the first (Ql) and the third quadrupole using a solution of polypropylene glycols (PPG's) in 3mMammoniumacetate. Samples were infused via a 75 fim i.d. fused silica capillary tubing to the ion spray tip which was held at a potential of 5.5 kV. A syringe pump (Model 22, Harvard Apparatus, MA,U.S.A.) controlled the delivery of the sample at a rate of 5.0 /^1/minute. Zero grade compressed air was used as nebulizer gas (pressure set at 55psi). A curtain gas (99.999% UHPnitrogen) flow of 0.8liter/minute was employed. The interface heater was set at 60°C. Mass spectra were obtained at a dwell time of 1.00msec (Ql scan range 300-^1800u, 10 scans averaged) and a step size of0.10u. The orifice voltage was maintained at 80V. All samples (ca. 100 /ig/ml) were dissolved, immediately prior to analysis, in a 0.1% aqueous TFA-MeOH1 : 1 mixture.
Elemental Analysis
Because of the minimumamount of final compounds, 
Phe3-TDHP, Methyl Ester (5a)
A solution of 1.8g (about 1.5mmol) of the above compound (4a) in 120ml of a MeOH-In HC1-DMF 6:2: 1 mixture was hydrogenated (1 atm, 25°C) in the presence of 1.5g of 5% Pd/C. The catalyst was filtered off and MeOHwas evaporated at 35°C under reduced pressure, then 100 ml ofH2O was added and the resulting solution extracted with 150ml of EtOAc. The organic layer was discarded and the resulting aqueous suspension was extracted with 130ml of n-BuOH. The butanolic phase was separated and concentrated at 30°C under reduced pressure to a volume of about 20ml. Onadding 1 50 ml ofEt2O the precipitated solid was collected (0.65 g, HPLC: Method A, Rt 17.5 minutes, titre about 75%) and used for the next step without any further purifica- Ester (7a), MDL 63,166
The above crude product (0.27 g) was dissolved at 10°C in 5ml of dry TFA. After 10 minutes, the solvent was evaporated at 15°C under reduced pressure. The oily residue was re-dissolved in 30ml ofa H2O-MeOH 1 : 1 mixture and the resulting solution was adjusted at pH 3.5 with 1n NaOH,then it was loaded on a column of 50 g of silanized Silica-gel. Column chromatography was performed as previously described obtaining 0.05 g of After stirring at 5°C for 3 hours and at room temperature for 13 hours, 100ml ofH2O was added and the resulting suspension was adjusted at pH 3 with 1n HC1. After extraction with n-BuOU (30ml x 2), the organic extract was washed sequentially with 15ml of H2O, saturated (JVg-BOC-Lys)3-TDHP, Methyl Ester (5b) A solution of 4b (75mg, 0.06mmol) in a MeOHAcOH20 : 1 mixture (7ml) was hydrogenated over 5% Pd/C at 1 atm and 25°C. The catalyst was filtered off, the solvents were evaporated at 35°C under reduced pressure to a volume of~2ml to which 20ml of Et2O was added to yield 55mg (0.05mmol) of 5b (HPLC: C system, Rt 10.3 minutes). of 5b in 2ml of DMF, 0.02ml (0.15mmol) of TEA and 55mg (0. 1 25 mmol) of di-BOC-D-lysine, TV-hydroxysuccinimide ester were added at room temperature. After 18 hours stirring, 20ml of H2Owas added and the resulting suspension was adjusted at pH 3 with In HC1. The suspension was extracted with EtOAc (10 ml x 2) and the organic layer was washed with water (10ml x 2), afterwards it was concentrated at 45°C to a small volume (about 1.5ml). On adding Et2O (30ml), the precipitated solid was collected (50mg; HPLC: C system, Rt 13.9 minutes) and used without purification for the preparation of 7b.
(D-Lys)1-(Lys)3-TD-DHP, Methyl Ester (7b), MDL 64, 945 Crude product 6b (50mg) was dissolved at 10°C in 1.5ml of dry TFA. After 10 minutes, Et2O (30ml) was added and the precipitated solid (50 mg) was collected;
7b was purified by preparative HPLC using a linear gradient MeCN-0.01m H3PO4, pH 2.6 (2->40% of MeCN, 35 minutes, flow rate 4.0ml) to give 14mg of pure 7b (HPLC: B system, Rt 8.3 minutes, titre 95%). To a stirred solution of 41mg (0.165mmol) of Nmethyl-Af-Boc-D-leucine in 0.6ml of dry DMF, 47mg (0.33 mmol) ofHOBThydrate was added at 5°C followed by 34mg (0.165mmol) of DCC. The reaction mixture was kept at 5°C for 16 hours and then it was filtered to remove a white precipitate, which was discarded. A pure solution of the title compoundwas used in the synthesis THE JOURNAL OF ANTIBIOTICS ogy, antibiotics, and antibiotic resistance. Nat. Prod. Rep. 9: 199-215, 1992 
